Document Detail


Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.
MedLine Citation:
PMID:  19667218     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Interferon beta is 1 of 2 first-line treatments for relapsing-remitting multiple sclerosis (MS). However, not all patients respond to interferon beta therapy, and to date there is a lack of surrogate markers that reliably correlate with responsiveness to interferon beta therapy in MS.
OBJECTIVE: To identify allelic variants that influence response to interferon beta therapy in patients with MS.
DESIGN: Genome-wide scan.
SETTING: Academic research. Patients Two hundred patients having relapsing-remitting MS treated with interferon beta and having a follow-up period of at least 2 years were classified as responders or nonresponders to treatment based on stringent clinical criteria.
MAIN OUTCOME MEASURES: In the first phase of the study, a pooling-based genome-wide association study of 428 867 single-nucleotide polymorphisms (SNPs) was performed in 53 responders and 53 nonresponders to interferon beta therapy. After applying several selection criteria, 383 SNPs were individually genotyped in an independent validation cohort of 49 responders and 45 nonresponders to interferon beta therapy using a different genotyping platform.
RESULTS: Eighteen SNPs had uncorrected P < .05 associated with interferon beta responder status in the validation cohort. Of these, 7 SNPs were located in genes that code for alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid-type glutamate receptor GRIA3, type 1 interferon-related proteins ADAR and IFNAR2, cell cycle-dependent protein CIT, zinc finger proteins ZFAT and ZFHX4, and guanosine triphosphatase-activating protein STARD13.
CONCLUSIONS: This study supports an underlying polygenic response to interferon beta treatment in MS and highlights the importance of the glutamatergic system in patient response to interferon beta therapy.
Authors:
Manuel Comabella; David W Craig; Carlos Morcillo-Suárez; Jordi Río; Arcadi Navarro; Marta Fernández; Roland Martin; Xavier Montalban
Related Documents :
3011968 - X-linkage of the early in vitro alpha/beta interferon response of mouse peritoneal macr...
3915178 - Nk-cell stimulating properties of a membrane proteoglycane from non-capsulated klebsiel...
6166278 - Tissue distribution of human interferons after exogenous administration in rabbits, mon...
16928608 - Autoimmune thrombocytopenia induced by peg-ifn-alpha plus ribavirin in hepatitis c.
19416808 - Transcellular biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal in...
2111908 - Antitumor activity in skin of skh and sencar mice by two dietary beta-carotene formulat...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Archives of neurology     Volume:  66     ISSN:  1538-3687     ISO Abbreviation:  Arch. Neurol.     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-08-11     Completed Date:  2009-08-20     Revised Date:  2013-02-11    
Medline Journal Info:
Nlm Unique ID:  0372436     Medline TA:  Arch Neurol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  972-8     Citation Subset:  AIM; IM    
Affiliation:
Centre d'Esclerosi Múltiple de Catalunya, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Edifici Escola d'Infermeria 2 feminine planta, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. mcomabel@ir.vhebron.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine Deaminase / genetics
Adult
Alleles*
Antineoplastic Agents / therapeutic use*
Cohort Studies
DNA Helicases / genetics
Female
Follow-Up Studies
Genome-Wide Association Study*
Genotype
Humans
Interferon-beta / therapeutic use*
Intracellular Signaling Peptides and Proteins
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting / drug therapy*,  genetics*
Polymorphism, Single Nucleotide / genetics*
Protein-Serine-Threonine Kinases
Receptor, Interferon alpha-beta / genetics
Receptors, AMPA / genetics
Recombinant Proteins / therapeutic use
Transcription Factors / genetics
Treatment Outcome
Tumor Suppressor Proteins / genetics
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/IFNAR2 protein, human; 0/Intracellular Signaling Peptides and Proteins; 0/Receptors, AMPA; 0/Recombinant Proteins; 0/STARD13 protein, human; 0/Transcription Factors; 0/Tumor Suppressor Proteins; 0/ZFAT protein, human; 0/glutamate receptor ionotropic, AMPA 3; 156986-95-7/Receptor, Interferon alpha-beta; 77238-31-4/Interferon-beta; EC 2.7.1.-/citron-kinase; EC 2.7.11.1/Protein-Serine-Threonine Kinases; EC 3.5.4.-/dsRNA adenosine deaminase; EC 3.5.4.4/Adenosine Deaminase; EC 3.6.1.-/DNA Helicases; EC 3.6.4.12/CHD3 protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging ...
Next Document:  Affect of seizures during gestation on pregnancy outcomes in women with epilepsy.